Publications by authors named "Tzellos T"
European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.
J Eur Acad Dermatol Venereol
December 2024
Introduction: This second part of the S2k guidelines is an update of the 2015 S1 European guidelines.
Objective: These guidelines aim to provide an accepted decision aid for the selection, implementation and assessment of appropriate and sufficient therapy for patients with hidradenitis suppurativa/acne inversa (HS).
Methods: The chapters have been selected after a Delphi procedure among the experts/authors.
Introduction: Currently, limited data are available on long-term use of dupilumab to treat atopic dermatitis (AD) in a multinational real-world setting. The aim of this analysis was to report the interim 1-year data for patients with AD enrolled in the GLOBOSTAD registry, including treatment patterns, dupilumab effectiveness and safety, and healthcare burden.
Methods: GLOBOSTAD is an ongoing, 5-year, multinational, prospective, observational study of adult/adolescent (aged ≥ 12 years at baseline) patients with AD who initiated dupilumab in real-world settings according to their local country-specific prescribing guidelines.
Introduction: The International Hidradenitis Suppurativa Severity Score System (IHS4) is a validated tool that measures inflammatory lesions, including draining tunnels, in hidradenitis suppurativa (HS).
Objective: To evaluate secukinumab efficacy using IHS4 in patients with moderate to severe HS.
Methods: Data from the SUNSHINE and SUNRISE trials, which assessed subcutaneous secukinumab 300 mg every 2 (SECQ2W) and 4 (SECQ4W) weeks in adults with moderate to severe HS, were analyzed.
Atopic dermatitis (AD) is a chronic and fluctuating disease. Optimal management of AD and related comorbidities requires seamless coordination across multiple layers of the healthcare system. The objective of this survey was to explore patients' experiences with current management of AD.
View Article and Find Full Text PDFDiscrepancies in hidradenitis suppurativa lesion characterization by providers and patients.
J Eur Acad Dermatol Venereol
January 2025
Article Synopsis
- - The study examines inconsistencies in how healthcare providers and patients identify and count lesions associated with hidradenitis suppurativa (HS), highlighting potential issues in the existing clinical response measurement tool, HiSCR, and the impact of rater training on trial outcomes.
- - An online survey of 47 members from the HISTORIC collaboration revealed significant variability in lesion classification, with many providers differing on whether lesions should be treated as single or multiple entities based on their morphology.
- - Findings suggest a need for standardized, consensus-driven guidelines for rater training in HS clinical trials to improve consistency in lesion characterization and potentially enhance trial results.
First steps into AI-supported hidradenitis suppurativa severity assessment.
J Eur Acad Dermatol Venereol
March 2024
Background: Melanoma disease patterns vary with patient age.
Aim: To evaluate sentinel lymph node biopsy (SLNB) in managing melanoma at differing patient ages.
Methods: Online prediction tools were applied to compare SLNB positivity (SLNB) and survival risk at patient ages 20-80.
Introduction: Insights into real-world treatment of atopic dermatitis (AD) are relevant to clinical decision making. The aim of this analysis was to characterize patients who receive dupilumab for AD in a real-world setting.
Methods: The GLOBOSTAD registry is an ongoing, longitudinal, prospective, observational study of patients with AD who receive dupilumab according to country-specific prescribing information.
Online prediction tools for melanoma survival: A comparison.
J Eur Acad Dermatol Venereol
October 2023
Background: Breslow thickness, patient age and ulceration are the three most valuable clinical and pathological predictors of melanoma survival. A readily available reliable online tool that accurately considers these and other predictors could be valuable for clinicians managing melanoma patients.
Objective: To compare online melanoma survival prediction tools that request user input on clinical and pathological features.
Article Synopsis
- A new parameter called IHS4-55, which indicates a 55% reduction in the severity of Hidradenitis Suppurativa (HS), was validated using data from patients treated with adalimumab and placebo.
- The research aimed to externally validate the IHS4-55 in patients treated with antibiotics, assessing its correlation with the reduction of inflammatory lesions and quality of life metrics.
- Results from a study of 283 patients showed that those achieving IHS4-55 experienced significant reductions in inflammatory nodules and had a greater likelihood of improving quality of life scores, supporting its use as a key outcome measure in clinical trials.
Article Synopsis
- A new dichotomous outcome measure, IHS4-55, was created and validated for assessing hidradenitis suppurativa (HS) in clinical trials and practice, focusing on a 55% reduction in the IHS4 score to indicate improvement.
- The effectiveness of the IHS4-55 was demonstrated through data from the PIONEER studies, showing that patients who met this threshold had better outcomes when treated with adalimumab compared to placebo.
- IHS4-55 shows similar performance to existing measures, providing a reliable tool for evaluating treatment responses in HS patients.
Background: Nearly half of patients with hidradenitis suppurativa (HS) report dissatisfaction with their treatment. However, factors related to treatment satisfaction have not been explored.
Objectives: To measure associations between treatment satisfaction and clinical and treatment-related characteristics among patients with HS.
Hidradenitis suppurativa/acne inversa (HS) is a chronic inflammatory disease of the pilosebaceous unit leading to formation of painful, inflammatory nodules, abscesses and tunnels in apocrine gland-bearing areas of the skin. Pain and drainage are the most important symptoms associated with reduction of quality of life in HS. On the other hand, an overlooked symptom in quality of life studies is itch, despite the fact that several studies have reported its importance.
View Article and Find Full Text PDF